Amyloid pet imaging: prime 1b study
Jeff Sevigny(Ovid Therapeutics (United States)), Jerome Barakos(Sutter Health), Joyce Suhy(BioClinica (United States)), Ajay Verma(Maulana Azad National Institute of Technology), Tianle Chen(Biogen (United States)), Gregory Klein(Roche (Switzerland)), Ping Chiao(Biogen (United States)), Mehul Sampat(Biogen (United States)), Joonmi Oh(Biogen (United States)), Derk D. Purcell(BioClinica (United States))
Cited by 0
Related Papers
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
|The Journal of Prevention of Alzheimer s Disease|2022|1.3k
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
|JAMA Neurology|2021|602
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
|Alzheimer s Research & Therapy|2017|568